# Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

> **NCT05477823** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** External beam radiation therapy
- **RADIATION:** Prostate brachytherapy boost
- **DRUG:** Androgen deprivation therapy
- **DIAGNOSTIC_TEST:** Positron emission tomography (PET)/magnetic resonance imaging (MRI)

## Key facts

- **NCT ID:** NCT05477823
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2026-04
- **Final completion:** 2027-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477823, "Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05477823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*